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Edited by Ned ManteiAbstract The a7 subunit is a component of nicotinic acetyl-
choline receptors expressed in bovine chromaﬃn cells. The
peculiar localization of these receptors at adrenomedullary areas
adjacent to the adrenal cortex suggests that factors, probably
glucocorticoids, arising from the cortex might diﬀuse and
regulate a7 receptor expression. In reporter gene transfection
experiments, dexamethasone increased a7 promoter activity by
up to ﬁvefold in a concentration- and time-dependent manner
despite the absence of consensus glucocorticoid receptor elements
at the a7 promoter. Transcriptional activation induced by
glucocorticoids was abolished through simultaneous mutation
of at least two of the three sites for the immediate early
transcription factor Egr-1, present in the proximal promoter
region of the a7 subunit gene. Therefore, glucocorticoids activate
the a7 subunit gene through Egr-1 in an indirect way.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Neuronal nicotinic acetylcholine receptors (nAChRs) are
pentameric oligomers composed of related subunits which are
commonly classiﬁed as agonist-binding (designated a2–a10)
and structural (b2–b4) subunits (reviewed in [1,2]). Consider-
able eﬀort has been dedicated to understanding how the re-
gional and developmental expression of neuronal nAChRs is
controlled at the transcriptional level (reviewed in [3]). Previ-
ously, we have characterized the promoters of the bovine a7
[4,5], a5 [6], and b4 [7] subunits which are components of
nAChRs present in chromaﬃn cells of the bovine adrenal
medulla. One of the subtypes, sensitive to a-bungarotoxin, is
formed by a7 subunits and is diﬀerentially expressed in ad-
renergic cells adjacent to the adrenal cortex [4]. Since the latter
may provide high levels of glucocorticoids to the contiguous
adrenergic cells, we asked whether the a7 promoter would be
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2.1. Plasmid constructions
The isolation and characterization of the 50 ﬂanking sequence of the
bovine a7 subunit gene has been previously described [4]. All a7 pro-
moter-LUC gene fusions were made in the pGL2-Basic vector (Pro-
mega, Spain), introducing in its polylinker, upstream of the luciferase
gene, the suitable a7 promoter fragments. The basic strategy for site-
directed mutagenesis of the diﬀerent elements at the )77 to )15 region
of the a7 promoter (see Fig. 2) has been previously described [5].
2.2. Cell culture and reporter assays
Chromaﬃn cells were isolated from bovine adrenal glands as de-
scribed [8] and cultured in 90% Dulbecco’s modiﬁed Eagle’s medium
(Sigma, Spain), 10% fetal calf serum, and 10 lM cytosine arabinoside
and 10 lM 5-ﬂuoro-20-deoxyuridine (Sigma) to prevent ﬁbroblast
proliferation. C2C12 cells were grown in 85% Dulbecco’s modiﬁed
Eagle’s medium (Sigma), and 15% fetal calf serum. Serum was treated
with charcoal to eliminate hormones [9] and medium contained no
phenol red [10].
Plasmids were puriﬁed by Concert columns (Invitrogen). Both cell
types were transfected by the calcium phosphate procedure [11].
Chromaﬃn cells on 48 wells-plates (5 105 cells/well) or C2C12 (104
cells/well) cells on 24 wells-plates were incubated with 0.75 lg of pGL2
vector or an equivalent amount (in molar terms) of the diﬀerent con-
structs derived from this vector, and with 0.75 lg of b-galactosidase
expression vector pCH110 (Amersham Pharmacia Biotech) as a con-
trol of transfection eﬃciency (amounts given per well). Cells were
washed the next day and dexamethasone treatment started immedi-
ately. Cells were harvested after 48 h and b-galactosidase and luciferase
were then determined in the lysates with the corresponding assay
systems (Promega). Luciferase activity was normalized to values ob-
tained with the p77a7LUC plasmid in the same cell type and condi-
tions but without dexamethasone treatment. Data were analyzed with
the Graphpad Prism program (Graphpad Software Inc.) applying the
ANOVA-Bonferroni’s multiple comparison test. Statistical signiﬁcance
was set to P < 0:05.
2.3. Electrophoretic mobility shift assay
Crude nuclear extracts were prepared from transfected C2C12 cells
as described [12]. Extracts from cells treated or not with 100 nM
dexamethasone for 48 h were compared. The DNA fragment corre-
sponding to the region )77 to +43 of the a7 promoter was obtained
and end-labeled by Klenow-ﬁlling as previously described [5]. The
conditions of the DNA–protein binding reactions have also been
described [5].3. Results and discussion
In order to examine the possibility that glucocorticoids
were activating the transcription of the a7 subunit gene, bovine
chromaﬃn cells were cotransfected with a plasmid coding
for the human glucocorticoid receptor (pRS-hGRa kindlyblished by Elsevier B.V. All rights reserved.
Fig. 1. Activation of the a7 subunit promoter by dexamethasone in
transfected C2C12 cells. A: Cells were transfected with the a7 pro-
moter-luciferase gene constructs p77a7LUC or p1011a7LUC plus the
glucocorticoid receptor expression plasmid pRS-hGRa and treated
with 100 nM dexamethasone for 48 h. Luciferase expression was de-
termined as described in Section 2, and activity was expressed as a
percentage with respect to values in cells transfected with p77a7LUC
and pRS-hGRa in the same conditions, but not treated with the glu-
cocorticoid. Data are meansS.E. (bars) values for two individual
experiments. All experimental points were performed in triplicate.
Basal activities of p77a7LUC and p1011a7LUC were not signiﬁcantly
diﬀerent. Dexamethasone activation was signiﬁcant in both cases B:
Activation of the a7 subunit promoter in C2C12 cells as a function of
time. Cells were transfected with p77a7LUC and pRS-hGRa and
treated with 100 nM dexamethasone for diﬀerent intervals. Activity
was expressed as a percentage with respect to values in cells cultured
and transfected in the same conditions but not treated with dexa-
methasone. C: Activation of the a7 subunit promoter in C2C12 cells as
a function of dexamethasone concentration. Cells were transfected
with construct p77a7LUC and treated with diﬀerent concentrations of
dexamethasone for 48 h. Luciferase activity was determined and ex-
pressed as indicated in panel A. Data from panels B and C are from
three or four experiments performed in triplicate.
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moter-luciferase gene construct p2700a7LUC, which contains
about 2700 bp of a7 promoter sequence plus 43 bp of 50 non-
coding region linked to the luciferase gene and yields the
maximal promoter activity in chromaﬃn cells [4]. The eﬀect of
the synthetic glucocorticoid dexamethasone on a7 promoter
activity was examined by measuring luciferase expression in
cells lysed at diﬀerent times of dexamethasone treatment. Al-
though a slight enhancement (118% of non-treated control) of
luciferase activity was already observed at 18 h after 100 nM
dexamethasone treatment, maximal activation (712%) was
obtained at 48 h.
To deﬁne the minimal promoter region that mediates glu-
cocorticoid activation, chromaﬃn cells were also transfected
with reporter constructs bearing nested 50 deletions of the a7
promoter fused to luciferase and further treated with 100 nM
dexamethasone during 48 h.Constructs bearing 1011, 665, 353,
128 and 77 bp of promoter sequence relative to the tran-
scriptional start site mediated dexamethasone-inducible gene
expression at levels comparable to the one observed with
p2700a7LUC. Therefore, the smaller tested construct,
p77a7LUC, contains the elements necessary for dexametha-
sone induction. We have previously shown that this construct
deﬁnes the minimal a7 promoter region required for optimal
gene expression in cultured chromaﬃn cells [5].
Although dexamethasone activation of the a7 promoter was
always observed in chromaﬃn cells, results were highly vari-
able when comparing diﬀerent cell batches, ranging between
two- and seven-fold activation. We think that this is a conse-
quence of donor heterogeneity, perhaps produced by diﬀerent
living conditions, hormonal treatments, age, etc. For this
reason, we decided to use the C2C12 cell line for a more de-
tailed study. We have previously shown that C2C12 muscle
cells express transcripts coding for the a7 subunit and that
their diﬀerentiation produced an increase in the amount of a7
transcripts, which is accompanied by the activation of the a7
core promoter [13]. In C2C12 cells we ﬁrst compared two
diﬀerent a7 promoter constructs, the ones containing 1011 and
77 bp of promoter sequence. They exhibited similar activation
of their transcriptional activity (Fig. 1A), as it was previously
observed in chromaﬃn cells. Dexamethasone stimulated re-
porter gene expression in a time-dependent manner (Fig. 1B).
Whereas activation was not signiﬁcant after 3 h, a fourfold
enhancement of luciferase activity produced by construct
p77a7LUC was observed at 24 h after 100 nM dexamethasone
treatment. An increase of about ﬁvefold was observed at 48 h
(statistically non-signiﬁcant when compared to the activation
observed at 24 h). Dexamethasone also exhibited activation of
reporter gene expression in a concentration-dependent manner
(Fig. 1C). A signiﬁcant stimulation of luciferase expression
was observed at 5 nM dexamethasone. Maximum activation
was observed at 5 lM, although saturation of the response was
evident at 50 nM. In fact, values obtained at 50 nM and higher
concentrations were not signiﬁcantly diﬀerent and we decided
to use a concentration of 100 nM dexamethasone in further
experiments. Cells non-transfected with the glucocorticoid re-
ceptor plasmid did not show dexamethasone activation of
p77a7LUC, as they do not express endogenous glucocorticoid
receptors, suggesting that the dexamethasone eﬀect is speciﬁc.
No consensus binding sites for glucocorticoid receptors have
been found at the a7 promoter, which is, however, activated by
the immediate-early gene product Egr-1 through its binding tothree closely located sites in the proximal promoter region [5].
Egr-1 can be rapidly induced by various extracellular stimuli
(reviewed in [14]), so we asked whether the dexamethasone
induction of the a7 promoter occurs through a mechanism
potentially dependent on Egr-1. Thus, we compared dexa-
methasone-induced luciferase activity expressed by the
wild-type promoter (p77a7LUC) and by derivatives of this
construct mutated at the Egr-1 binding sites and also at an
USF site required for maximal transcriptional activity (see
AB
Fig. 2. (A) Egr-1 sites in the proximal promoter region of the a7 gene
are involved in glucocorticoid activation. The nucleotide sequence
(nucleotides )77 to )12) of the bovine a7 subunit gene promoter is
shown at the top. Egr-1 and USF regulatory elements are indicated
(ﬁlled boxes, numbered 1–4). Several nucleotides of each element were
mutated, individually or simultaneously, in the parent construct
p77a7LUC to yield mutant derivatives that were transfected in C2C12
cells together with pRS-hGRa. The name of each mutant construct
indicates the element(s) that have been altered (also crossed out in the
schematic diagram of panel B). Luciferase activity was determined as
indicated in Fig. 1 and normalized to values obtained with the
p77a7LUC construct. Open boxes indicate luciferase activity of the
diﬀerent constructs in untreated control cells, whereas solid boxes in-
dicate activity in cells treated with 100 nM dexamethasone for 48 h.
Numbers above the columns indicate the fold induction by dexa-
methasone relative to the activity of the same construct in untreated
cells. Data are from two experiments performed in triplicate.
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(boxes 1, 2 and 4 at Fig. 2A) did not have any signiﬁcant eﬀect
on dexamethasone induction observed with the non-mutated
construct (results not shown). However, simultaneous muta-
tion of two of the three Egr-1 binding elements (sites 1 and 2)
clearly reduced dexamethasone induction to statistically non-
signiﬁcant levels (Fig. 2B, pmut 2-1 a7LUC). The additional
mutation of Egr-1 site 4 did not aﬀect dexamethasone induc-
tion further (Fig. 2B, pmut 4-2-1 a7LUC). Suppression of the
USF site alone did not aﬀect dexamethasone activation
(Fig. 2B, pmut 3 a7LUC), whereas the simultaneous mutation
of this site and Egr-1 sites 1 and 2 totally abolished hormonal
activation (Fig. 2B, pmut 3-2-1 a7LUC). These results indicate
that Egr-1 sites are required for maximal induction of the a7
promoter in response to glucocorticoids.
The involvement of Egr-1 in the glucocorticoid activation of
the a7 gene was further analyzed by gel mobility shift assays.
Since the highest induction in the a7 promoter was obtained
after 48 h of treatment, we prepared nuclear extracts from
C2C12 cells transfected with the glucocorticoid receptor plas-
mid and treated or not with 100 nM dexamethasone for this
time, and compared the pattern of complexes obtained with an
a7 probe covering from )77 to +43, in the minimal promoter
region. The probe showed the same pattern with nuclear ex-
tracts from treated and untreated cells (not shown). Moreover,
the main complexes, due to the binding of USF and Egr-1 (see
[13]), had the same intensity in both extracts, suggesting that
the glucocorticoid activation of the a7 gene does not involve
an increase in the amount of Egr-1 or the emergence of new
complexes. A possibility would be that glucocorticoids couldinduce post-translational modiﬁcations of Egr-1 that might
enhance its transactivation ability. For instance, phosphory-
lation [15], the redox state of Egr-1 [16] or the interaction with
corepressors [17] might modify its DNA binding capacity.
Whatever the mechanism, in the bovine adrenal gland a spe-
ciﬁc stimulation of Egr-1 function by glucocorticoids appears
very plausible, since localization of adrenergic cells expressing
Egr-1 and also the enzyme phenylethanolamine N-methyl
transferase (PNMT) and a7 nAChRs is so peculiar: they are
only in the region of the adrenal medulla close to the adrenal
cortex and to the portal vein [4]. In this scenario, glucocor-
ticoids arising from the cortex would diﬀuse into the nearby
area of the adrenal medulla and then act directly on adrenergic
chromaﬃn cells, especially because the glucocorticoid receptor
has been localized only to the cytoplasm of adrenergic cells
[18]. Egr-1, in turn, would activate the promoter of PNMT [19]
and a7 [4,5] genes. Recently, two overlapping glucocorticoid
response elements have been identiﬁed in the promoter of the
rat PNMT gene, which are primarily responsible for its glu-
cocorticoid sensitivity [20]. We could not detect such elements
in a sequence of about 1500 bp of the a7 gene promoter.
Moreover, the smallest construct p77a7LUC showed gluco-
corticoid activation, hence it can be concluded that in the case
of the a7 gene, glucocorticoid activation is indirect, through
the Egr-1 elements. This might also explain, at least partially,
why it is necessary to transfect glucocorticoid receptor DNA
into chromaﬃn cells to observe activation of the a7 promoter
by dexamethasone: the concentration of endogenous hormone
receptor may not be high enough for such an indirect eﬀect to
take place.
Finally, it is interesting to notice the central role that this
transcription factor plays in the integration of signals that
regulate the expression of the a7 gene. Thus, we have previ-
ously shown that the a7 promoter is activated by phorbol es-
ters [21] and also during muscle diﬀerentiation [13]. In both
cases, activation takes place through the Egr-1 sites previously
mentioned. Therefore, it is reasonable to expect that other
physiological stimuli that increase Egr-1 expression (see [22]
for a review), such as the ones driving to neuronal stimulation
[23,24], could also activate the nAChR a7 subunit gene.
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